Related Experiment Video
Updated: Sep 10, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in
1Food and Drug Administration, Division of Bioequivalence, Rockville, Maryland 20857.
Abstract:
The influence of random error and elimination rate on estimates of the area under the curve from zero to time infinity (AUCO-INF) was determined in a simulation study using noninfinity measured AUC values (i.e. AUCTM, area to a measured common sampling time, and AUCO-LAST, area to the last measured sampling time). Further, the extent of absorption of generic danazol, baclofen, and oxazepam was determined using measured methods of estimating area under the curve in bioequivalence studies. The noninfinity AUC estimates and their 90% confidence intervals for the difference in product means were compared for each individual drug. Products chosen fulfilled one of the following three criteria: (1) a high "apparent intrasubject variability" and a half-life greater than 8 hr (danazol); (2) a low apparent intrasubject variability and a half-life less than 4 hr (baclofen); and (3) products exhibiting a low apparent intrasubject variability and a half-life greater than 8 hr (oxazepam). For the simulated data, AUCTM performed best when subjects had similar half-lives (i.e., low variability), which results in AUCTM = AUCO-LAST. On the other hand, AUCO-LAST worked best with a high fractional standard deviation (fsd) and a short elimination half-life (i.e., less than 4 hr). The noninfinity 90% confidence intervals for danazol and oxazepam were inconsistent with those observed at AUCO-INF.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the lowest drug...
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's overall...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Measurement of Bioavailability: Pharmacokinetic Methods
Bioequivalence Data: Statistical Interpretation
Pharmacodynamic Models: Overview

